About CellCarta
CellCarta is a company based in Montreal (Canada) founded in 2000 was acquired by Arsenal Capital Partners in July 2019.. CellCarta has raised $7.5 million across 4 funding rounds from investors including Waters Corporation, HHS and Arsenal Capital Partners. CellCarta has completed 7 acquisitions, including Biogazelle, Clinical Logistics and ImmuneHealth. CellCarta offers products and services including CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services. CellCarta operates in a competitive market with competitors including Blue Rock Therapeutics, Impel Pharmaceuticals, Ascend, RiboPro and Invivyd, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.5 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Waters Corporation
& 6 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Biogazelle
& 6 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CellCarta
CellCarta offers a comprehensive portfolio of products and services, including CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cytometry analysis tool for research and data processing in labs.
Assesses immune responses through various cellular assays and tests.
Offers DNA sequencing and PCR for therapeutic development applications.
Provides tissue analysis and digital pathology for medical research.
Unlock access to complete
Unlock access to complete
Funding Insights of CellCarta
CellCarta has successfully raised a total of $7.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2014 | Amount | Grant - CellCarta | Valuation |
investors |
|
| Sep, 2009 | Amount | Grant - CellCarta | Valuation |
investors |
|
| Feb, 2009 | Amount | Series A - CellCarta | Valuation | Waters Corporation |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CellCarta
CellCarta has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Waters Corporation, HHS and Arsenal Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on company buyouts
|
Founded Year | Domain | Location | |
|
Private equity investments target specialty industrials and healthcare sectors.
|
Founded Year | Domain | Location | |
|
Specialist healthcare investment advisory services are provided by GHO Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CellCarta
CellCarta has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Biogazelle, Clinical Logistics and ImmuneHealth. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pathology services and solutions are provided for researchers.
|
2012 | ||||
|
Multi-parameter cell analysis systems are developed for high-content screening.
|
2008 | ||||
|
Immune responses to cancer immunotherapies in clinical trials are monitored.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - CellCarta
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellcarta Comparisons
Competitors of CellCarta
CellCarta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, Impel Pharmaceuticals, Ascend, RiboPro and Invivyd, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| domain | founded_year | HQ Location |
Transformative therapies are developed and commercialized through specialized services.
|
|
| domain | founded_year | HQ Location |
Online insurance payments and premium financing are enabled for businesses.
|
|
| domain | founded_year | HQ Location |
Online supplier and developer of RNA based products
|
|
| domain | founded_year | HQ Location |
Stem cell drug research and clinical trial services are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellcarta
Frequently Asked Questions about CellCarta
When was CellCarta founded?
CellCarta was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Where is CellCarta located?
CellCarta is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Who is the current CEO of CellCarta?
David Spaight is the current CEO of CellCarta.
Is CellCarta a funded company?
CellCarta is a funded company, having raised a total of $7.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Jun 28, 2007.
What does CellCarta do?
Founded in 2000 and based in Montreal, Canada, CellCarta operates as a contract research organization in the biotechnology sector. A range of services is provided, including histopathology, genomics, biomarker platforms, antigen presentation, bioanalytical solutions, bioinformatics, data mining, biologics characterization, and immune profiling. Access to these offerings supports research and development needs in the industry.
Who are the top competitors of CellCarta?
CellCarta's top competitors include Blue Rock Therapeutics, Ascend and RiboPro.
What products or services does CellCarta offer?
CellCarta offers CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services.
How many acquisitions has CellCarta made?
CellCarta has made 7 acquisitions, including Biogazelle, Clinical Logistics, and ImmuneHealth.
Who are CellCarta's investors?
CellCarta has 7 investors. Key investors include Waters Corporation, HHS, Arsenal Capital Partners, The Michael J. Fox Foundation, and Great Point Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.